SCM
FOLD

Stevens Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Stevens Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16,824
Closed -$92K – 976
2016
Q2 		$92K Buy
+16,824
New +$118K ﹤0.01% 838

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stevens Capital Management's FOLD Position: Q3 2016 in Review

Stevens Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2016, closing a stake of 16,824 shares — an estimated $92K sold.

Stevens Capital Management first reported a position in FOLD in Q2 2016 and held it in 1 quarter. The position peaked at $92K in Q2 2016. 136 funds tracked by Wall St. Rank hold FOLD as of Q3 2016.

  • Stevens Capital Management reported no remaining Amicus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Stevens Capital Management sold 16,824 Amicus Therapeutics shares in Q3 2016, an estimated $92K.
  • Stevens Capital Management first reported a position in Amicus Therapeutics in Q2 2016 and held it in 1 quarter.
  • Stevens Capital Management's Amicus Therapeutics position peaked at $92K in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2016.

Based on Stevens Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.